Vaccine period is the time boom for glove demand. All major glove maker already foresight these huge increasing huge, Topglove and supermax are now aggressively expand further its current capacity, topglove to produce 100 billion glove pa next year, growth of 25% from current 75 billion pa. Top glove to boost further capacity to further 140 billion by end 2025. On the other hand, supermax to boost capacity to 32 billion by next year from current 26 billion and further boost to 46 billion by 2023.

Glove demand is growing rapidly even at time of just screening test for covid, which is less than 5% of population. What will glove demand for vaccination if 50% of the population needed for protection?

To screening less than 5% population now, it take almost 3 month in US, what will vaccination time to take for 50% population? The glove demand is not only to growth rapidly but also at prolong period once vaccination period begin.

Vaccine development mostly funded by Government globally, therefore, once develop, it will administered widely to almost entire population in the world. Therefore, once vaccine become available publicly, Gov may require all people to be vaccinated especially in US, European region.

Those patient recover from covid virus only have antibody effective last for 2 month. Will coming vaccine can last for how long protection remain in ?

Glove demand is growing rapidly even at time of just screening test covid, which is less than 5% of population. What will glove demand for vaccination if 50% of the population needed for protection?

To screening less than 5% population now, it take almost 3 month in US, what will vaccination time to take for 50% population? The glove demand is not only to growth rapidly but also at prolong period once vaccination period begin.

Vaccine development mostly funded by Government globally, therefore, once develop, it will administered widely to almost entire population in the world. Therefore, once vaccine become available publicly, Gov may require all people to be vaccinated especially in US, European region.

To boost effective protection against covid, it may need multiple dose at interval time to upkeep protective antibody against covid.

https://www.chinapress.com.my/20200619/%e2%97%a4%e5%85%a8%e7%90%83%e5%a4%a7%e6%b5%81%e8%a1%8c%e2%97%a2-%e7%a0%94%e7%a9%b6%ef%bc%9a%e6%9f%93%e7%96%ab%e5%ba%b7%e5%a4%8d%e5%90%8e-%e6%8a%97%e4%bd%93%e6%81%90%e5%8f%aa%e7%bb%b4%e6%8c%812/

Those patient recover from covid virus only have antibody effective last for 2 month. Will coming vaccine can last for how long protection remain in ?

Glove demand is growing rapidly even at time of just screening test covid, which is less than 5% of population. What will glove demand for vaccination if 50% of the population needed for protection?

To screening less than 5% population now, it take almost 3 month in US, what will vaccination time to take for 50% population? The glove demand is not only to growth rapidly but also at prolong period once vaccination period begin.

Vaccine development mostly funded by Government globally, therefore, once develop, it will administered widely to almost entire population in the world. Therefore, once vaccine become available publicly, Gov may require all people to be vaccinated especially in US, European region.

To boost effective protection against covid, it may need multiple dose at interval time to upkeep protective antibody against covid.

https://www.chinapress.com.my/20200619/%e2%97%a4%e5%85%a8%e7%90%83%e5%a4%a7%e6%b5%81%e8%a1%8c%e2%97%a2-%e7%a0%94%e7%a9%b6%ef%bc%9a%e6%9f%93%e7%96%ab%e5%ba%b7%e5%a4%8d%e5%90%8e-%e6%8a%97%e4%bd%93%e6%81%90%e5%8f%aa%e7%bb%b4%e6%8c%812/

Glove demand is growing rapidly even at time of just screening covid, which is less than 5% of population. What will glove demand for vaccination if 50% of the population needed for protection?

To screening less than 5% population now, it take almost 3 month in US, what will vaccination time to take for 50% population? The glove demand is not only to growth rapidly but also at prolong period once vaccination period begin.

Glove demand is growing rapidly even at time of just screening covid, which is less than 5% of population. What will glove demand for vaccination if 50% of the population needed for protection?

To screening less than 5% population now, it take almost 3 month in US, what will vaccination time to take for 50% population? The glove demand is not only to growth rapidly but also at prolong period once vaccination period begin.

Glove demand is growing rapidly even at time of just screening covid, which is less than 5% of population. What will glove demand for vaccination if 50% of the population needed for protection?

To screening less than 5% population now, it take almost 3 month in US, what will vaccination time to take for 50% population? The glove demand is not only to growth rapidly but also at prolong period once vaccination period begin.

Well said, thumb up.

Glove profit growth still at infancy stage. It is yet to unleash fully as current ASP hike of 20% yet to account into topglove Q result. Topglove only account 5% in latest Q result as ASP hike only begin in April, but price locked in 1 month ahead, therefore, topglove only account mere ASP 5%hike impact in month of May for its financial year Mar-May. Therefore, topglove ASP further hike impact 20% only can record in fully in June-Aug.

Supermax, the sole OEM + OBM business model even will record much higher explosive profit growth as its ASP is based on spot price which is 200% - 300% higher than ASP by OEM ( topglove, harta, Kossan) of just 20%.

All ASP hike is direct translate go to bottom line straightly. Based on historical net profit margin of glove maker around 10%: A 10% ASP hike direct to 100% profit growth, a 100% ASP hike direct to 1000% profit growth.

consolidate now before regain momentum to bounce back strongly. Dowside riosk is limited, but odds for upside is bigger now.

bought back all supermax at 7.19-7.20

sold back at 7.45-7.46

bought back all supermax at 7.17-7.18

Cut all supermax at 7.25-7.30

Northcape, an Australia-headquartered asset manager that has been investing in the shares of glove makers for more than a decade, bought more glove-makers’ shares early this year “when signs emerged that Covid-19 would become a global pandemic,” Cameron said.

According to his calculations, Top Glove will generate average earnings growth of more than 100% for each of the next two years while Hartalega will also deliver “exceptionally strong” earnings growth as personal protective equipment purchases increase globally.

Some glove makers have “an order backlog all the way out to June 2021,” compared with one month before the pandemic, he said. The discovery of a vaccine to prevent Covid-19 disease will also help keep demand elevated because “glove companies and some experts have noted that the ”widespread administering of a vaccine will actually result in a further spike in glove demand, he added.


Important Remark: widespread administering of a vaccine will actually result in a further spike in glove demand,

Northcape, an Australia-headquartered asset manager that has been investing in the shares of glove makers for more than a decade, bought more glove-makers’ shares early this year “when signs emerged that Covid-19 would become a global pandemic,” Cameron said.

According to his calculations, Top Glove will generate average earnings growth of more than 100% for each of the next two years while Hartalega will also deliver “exceptionally strong” earnings growth as personal protective equipment purchases increase globally.

Some glove makers have “an order backlog all the way out to June 2021,” compared with one month before the pandemic, he said. The discovery of a vaccine to prevent Covid-19 disease will also help keep demand elevated because “glove companies and some experts have noted that the ”widespread administering of a vaccine will actually result in a further spike in glove demand, he added.


Important Remark: widespread administering of a vaccine will actually result in a further spike in glove demand,

Northcape, an Australia-headquartered asset manager that has been investing in the shares of glove makers for more than a decade, bought more glove-makers’ shares early this year “when signs emerged that Covid-19 would become a global pandemic,” Cameron said.

According to his calculations, Top Glove will generate average earnings growth of more than 100% for each of the next two years while Hartalega will also deliver “exceptionally strong” earnings growth as personal protective equipment purchases increase globally.

Some glove makers have “an order backlog all the way out to June 2021,” compared with one month before the pandemic, he said. The discovery of a vaccine to prevent Covid-19 disease will also help keep demand elevated because “glove companies and some experts have noted that the ”widespread administering of a vaccine will actually result in a further spike in glove demand, he added.


Important Remark: widespread administering of a vaccine will actually result in a further spike in glove demand,

Northcape, an Australia-headquartered asset manager that has been investing in the shares of glove makers for more than a decade, bought more glove-makers’ shares early this year “when signs emerged that Covid-19 would become a global pandemic,” Cameron said.

According to his calculations, Top Glove will generate average earnings growth of more than 100% for each of the next two years while Hartalega will also deliver “exceptionally strong” earnings growth as personal protective equipment purchases increase globally.

Some glove makers have “an order backlog all the way out to June 2021,” compared with one month before the pandemic, he said. The discovery of a vaccine to prevent Covid-19 disease will also help keep demand elevated because “glove companies and some experts have noted that the ”widespread administering of a vaccine will actually result in a further spike in glove demand, he added.


Important Remark: widespread administering of a vaccine will actually result in a further spike in glove demand,

1. Top glove revenue rose 37% due to higher sales volume (+25%) and ASP (+5%). Correspondingly, PBT margin improved by a massive 14.4ppt to 25% compared to 10.6% in 2QFY20 due to higher ASP which theoretically flow straight down to bottom-line. Top glove latest financial ending May only manage to record 5% hike in ASP, already can record more than double profit.

More boom profit will record in next Q result after record current ASP hike 20%, more than triple increase in EPS in next Q result as all increase in ASP direct go to increase net profit margin.

2. Comfort financial year ending April still yet to record impact on ASP which only took effect begin May. But, just through increase sale volume, productivity already can record double profit. Next Q result will record full impact ASP on profit. But, as small OEM, the ASP could be 10%, therefore, next Q result EPS 5 sen

3. Supermax financial ending Mar, only manage to record least impact of surge in sale demand, but able to capture small ASP due to it have own distribution division. The full impact on ASP in OEM factory price hike 20% + OBM distributors 100-150% hike will only able to record in next Q result. As ASP hike direct go to bottom line, Expect Superman to deliver quadruple EPS 20sen in next Q result.

1. Top glove revenue rose 37% due to higher sales volume (+25%) and ASP (+5%). Correspondingly, PBT margin improved by a massive 14.4ppt to 25% compared to 10.6% in 2QFY20 due to higher ASP which theoretically flow straight down to bottom-line. Top glove latest financial ending May only manage to record 5% hike in ASP, already can record more than double profit.

More boom profit will record in next Q result after record current ASP hike 20%, more than triple increase in EPS in next Q result as all increase in ASP direct go to increase net profit margin.

2. Comfort financial year ending April still yet to record impact on ASP which only took effect begin May. But, just through increase sale volume, productivity already can record double profit. Next Q result will record full impact ASP on profit. But, as small OEM, the ASP could be 10%, therefore, next Q result EPS 5 sen

3. Supermax financial ending Mar, only manage to record least impact of surge in sale demand, but able to capture small ASP due to it have own distribution division. The full impact on ASP in OEM factory price hike 20% + OBM distributors 100-150% hike will only able to record in next Q result. As ASP hike direct go to bottom line, Expect Superman to deliver quadruple EPS 20sen in next Q result.

1. Top glove revenue rose 37% due to higher sales volume (+25%) and ASP (+5%). Correspondingly, PBT margin improved by a massive 14.4ppt to 25% compared to 10.6% in 2QFY20 due to higher ASP which theoretically flow straight down to bottom-line. Top glove latest financial ending May only manage to record 5% hike in ASP, already can record more than double profit.

More boom profit will record in next Q result after record current ASP hike 20%, more than triple increase in EPS in next Q result as all increase in ASP direct go to increase net profit margin.

2. Comfort financial year ending April still yet to record impact on ASP which only took effect begin May. But, just through increase sale volume, productivity already can record double profit. Next Q result will record full impact ASP on profit. But, as small OEM, the ASP could be 10%, therefore, next Q result EPS 5 sen

3. Supermax financial ending Mar, only manage to record least impact of surge in sale demand, but able to capture small ASP due to it have own distribution division. The full impact on ASP in OEM factory price hike 20% + OBM distributors 100-150% hike will only able to record in next Q result. As ASP hike direct go to bottom line, Expect Superman to deliver quadruple EPS 20sen in next Q result.

1. Top glove revenue rose 37% due to higher sales volume (+25%) and ASP (+5%). Correspondingly, PBT margin improved by a massive 14.4ppt to 25% compared to 10.6% in 2QFY20 due to higher ASP which theoretically flow straight down to bottom-line. Top glove latest financial ending May only manage to record 5% hike in ASP, already can record more than double profit.

More boom profit will record in next Q result after record current ASP hike 20%, more than triple increase in EPS in next Q result as all increase in ASP direct go to increase net profit margin.

2. Comfort financial year ending April still yet to record impact on ASP which only took effect begin May. But, just through increase sale volume, productivity already can record double profit. Next Q result will record full impact ASP on profit. But, as small OEM, the ASP could be 10%, therefore, next Q result EPS 5 sen

3. Supermax financial ending Mar, only manage to record least impact of surge in sale demand, but able to capture small ASP due to it have own distribution division. The full impact on ASP in OEM factory price hike 20% + OBM distributors 100-150% hike will only able to record in next Q result. As ASP hike direct go to bottom line, Expect Superman to deliver quadruple EPS 20sen in next Q result.

bought back all supermax at 8.74-8.76

take all profit first, await for top glove result release before re-enter back

sold off all supermax at 8.75-8.76

Capitalize on today healthy correction to re-enter back again

bought back all supermax at 8.38

add bjland at 18sen

add bjcorp at 18.5sen

Russia today declare the peak of covid case have over.

sold back master at 2.09-2.10

sold back supermax at 9.22-9.24

The number of new case is keep increasing trend, record exceed 100k case every day. It is getting worsen rather than subside.

Even if vaccines found, how effective and how many time dose need to inject and can how long last the vaccines protection against virus. The virus unlike any other SAS or HINI, it spread for so rapidly, long and have infected million of people, the fatality rate of more than 5% and easy route of infection remain a risk of recurring pandemic through virus mutation.

Different vibrant of virus already found, type a, b, and c and it can continue evolve in future. The pathogenic of virus is prove capable of evolving. Global healthcare awareness is increasing, demanding personal protection become new normal in future not only confine into medical field, but more importantly, the increasing demand from non-medical field to avoid foreclosure risk if new case found.

First Epicenter of Covid-9
1. China
2. Italy

Current epicenter of Covid-9
1. US
2. Russia
2. Brazil

Next epicenter of covid-9
1. India
2. Pakistan
3. Bandgalesh
4. South African



South Africa's COVID-19 cases rise and president worries about Cape Town region

CAPE TOWN - Even as South Africa eases its coronavirus lockdown, infection numbers have started to rise quickly and President Cyril Ramaphosa said on Friday he was particularly concerned about the province around Cape Town.

Western Cape, whose Table Mountain and wine tours make it a leading tourist destination, has become the country's main coronavirus hotspot, with around two-thirds of the country's total 40,792 cases. It has also recorded 651 out of the the country's total of 848 deaths.

South Africa recorded its largest daily jump of cases on Thursday, with 3,267 new cases.

Ramaphosa visited Cape Town on Friday to be briefed on efforts to tackle the virus, including the opening of a new temporary field hospital for mild to moderately sick patients.

"The Western Cape is the epicentre for COVID-19 infections and this concerns us deeply," he said.

The government is expecting an escalation of cases ahead of a predicted August/September peak and rising community infection rates in densely-packed poor townships. But it is struggling with shortages of test kits, healthcare staff and hospital beds.

"We must increase the number of beds ... It's better to over provide than to under provide because the worst is still to come," Ramaphosa said.

Th number of new case is keep increasing trend, record exceed 100k case every day. It is getting worsen rather than subside.

Even if vaccines found, how effective and how many time dose need to inject and can how long last the vaccines protection against virus. The virus unlike any other SAS or HINI, it spread for so rapidly, long and have infected million of people, the fatality rate of more than 5% and easy route of infection remain a risk of recurring pandemic through virus mutation.

Different vibrant of virus already found, type a, b, and c and it can continue evolve in future. The pathogenic of virus is prove capable of evolving. Global healthcare awareness is increasing, demanding personal protection become new normal in future not only confine into medical field, but more importantly, the increasing demand from non-medical field to avoid foreclosure risk if new case found.

First Epicenter of Covid-9
1. China
2. Italy

Current epicenter of Covid-9
1. US
2. Russia
2. Brazil

Next epicenter of covid-9
1. India
2. Pakistan
3. Bandgalesh
4. South African



South Africa's COVID-19 cases rise and president worries about Cape Town region

CAPE TOWN - Even as South Africa eases its coronavirus lockdown, infection numbers have started to rise quickly and President Cyril Ramaphosa said on Friday he was particularly concerned about the province around Cape Town.

Western Cape, whose Table Mountain and wine tours make it a leading tourist destination, has become the country's main coronavirus hotspot, with around two-thirds of the country's total 40,792 cases. It has also recorded 651 out of the the country's total of 848 deaths.

South Africa recorded its largest daily jump of cases on Thursday, with 3,267 new cases.

Ramaphosa visited Cape Town on Friday to be briefed on efforts to tackle the virus, including the opening of a new temporary field hospital for mild to moderately sick patients.

"The Western Cape is the epicentre for COVID-19 infections and this concerns us deeply," he said.

The government is expecting an escalation of cases ahead of a predicted August/September peak and rising community infection rates in densely-packed poor townships. But it is struggling with shortages of test kits, healthcare staff and hospital beds.

"We must increase the number of beds ... It's better to over provide than to under provide because the worst is still to come," Ramaphosa said.

bought back max supermax at 8.79

sold back mtag at 55sen, entitle 2 sen dividend

bought back mtag at 56.5sen

cut mtag at 57sen

sold back all bstead at 69sen

bought master at 2.05-2.06

sold back all supermax at 8.07

sold back all comfort at 3.57

Sslee

The four season is joint control equally by bjcorp and bjland. Bjcorp control 78% bjland, therefore, in turn of profit attributed to shareholder, bjcorp shareholder benefited to most.

Shareholder now can request for special dividend via online EGM since bjcorp monetize four season have EXTRA gain RM 190m on top of already net gain RM 480m as disposal is now revise up earlier RM 1,87 billion to RM 2.06 billion

Bjcrop to acquire singer is just MOU. It NO yet to sign any purchase document, therefore no need shareholder approval at all. THe MOU still subject to due diligence account check before to sign purchase document.

The latest EGM call is for four season disposal for RM 2.06 billion instead of earlier RM 1.86 billion. Bjcrop need to seek forgiven from shareholder in EGM for their mistake in under declare on gain of disposal.

RATIFICATION OF THE DISPOSAL OF THE HOTEL COMPONENT OF FOUR SEASONS HOTEL & HOTEL RESIDENCES KYOTO IN JAPAN (“HOTEL”) FOR A TOTAL CASH CONSIDERATION OF JPY50.79 BILLION (EQUIVALENT TO APPROXIMATELY RM2.06 BILLION), BEING THE SALE CONSIDERATION OF JPY49.00 BILLION (EQUIVALENT TO APPROXIMATELY RM1.99 BILLION) PLUS THE BUILDING CONSUMPTION TAX OF JPY1.79 BILLION (EQUIVALENT TO APPROXIMATELY RM72.52 MILLION) DUE TO THE TAX AUTHORITY OF JAPAN AND THE SUBSEQUENT LEASEBACK OF THE HOTEL ("TRANSACTION") (“RATIFICATION”)

Remark: bjjcorp rectify that selling price four season from earlier RM 1.87 billion to now at RM 2.06 billion, a increase of RM 190m

average down cost

add all balance capital at 2.63

bought supermax at 7.10

bought mtag at 57.5sen

bought comfort at 3.25

The upcoming REAL catalyst is Bjcorp will record massive net gain RM 480m after tax from disposal four season hotel in japan, nett EPS = 9sen.

DISPOSAL AND LEASEBACK OF THE HOTEL COMPONENT OF FOUR SEASONS HOTEL & HOTEL RESIDENCES KYOTO, JAPAN

On behalf of the Board, Maybank IB wishes to announce that the Disposal was completed today following the settlement of the Total Consideration by the Purchaser in cash and BKD has on even date entered into the Lease Agreement with the Trustee and the Purchaser.

This Announcement is dated 10 March 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3028849